Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20033 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Overall survival (OS) is considered the most reliable cancer endpoint and used by the Health Rregulatory authorities (HRA). OS presents multiple advantages in cancer randomized controlled trials (RCT): it is universally accepted as a measure of clinical benefit for the patient; it is objectively defined, both in terms of events and date of incidence; it is easily and precisely measured and thus reproducible; it can be exhaustively collected. As such, OS has been validated by HRAs. On the other hand, OS presents some limitations. Observing a benefit on OS may require a large number of patients and/or considerable time for patient follow-up. Costs for trials may be increased, and there might be delays in the introduction of possible beneficial treatments for patients. The development of alternative endpoints that could capture treatment benefit appropriately and be measurable earlier, is central for the evolution of clinical research in oncology.

Real world data (RWD) are defined as other sources than clinical trials such as: electronic medical records, registries, insurance claims, pharmacy records, death certificates and other patient-generated data.

This research is aimed at (i) describing the existing endpoints of survival in real-life setting, (ii) comparing the correlation at individual level with data to clinical trials for related to anti-HER2 targeted therapies and endocrine therapies in MBC. We will investigate the individual correlation between candidate surrogate endpoints and overall survival in a population-based record-computerized database centralizing data on about 20,000 patients from 2008 to 2017 in France.

This work should lead to the estimation of various time-to event endpoints (e.g. OS, PFS, etc), in the real-life setting, for mBC patients. In addition, we will estimate their individual correlation with OS, which should help us highlight potential surrogate endpoints in this setting. We will focuss on three distinct population, accounting for a large population of mBS patients: : patients treated with anti-HER2 targeted agents, patients treated with endocrine therapies and elderly population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

NCT01574170

Metastatic Breast Cancer Starting a Third Line Chemotherapy

COMPLETED PHASE4

GW572016 For Treatment Of Refractory Metastatic Breast Cancer

NCT00062686

Neoplasms, Breast

COMPLETED PHASE2

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

NCT03275311

Metastatic Breast Cancer

RECRUITING

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NCT06197581

Breast Cancer, Familial Male Radiotherapy; Complications Chemotherapeutic Toxicity +5 more

RECRUITING NA

Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

NCT02089100

Breast Cancer

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with a diagnosis of HR+ /HER2- metastatic breast cancer (mBC)

Chemotherapy (exclusive)

Intervention Type DRUG

Administration of any chemotherapeutic agent(s)

Endocrine therapy (exclusive)

Intervention Type DRUG

Administration of any type of endocrine therapy

Combination of endocrine therapy and chemotherapy

Intervention Type DRUG

Any combination of endocrine therapy and chemotherapy

Chemotherapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy and targeted treatment(s)

Combination of endocrine therapy and targeted treatment

Intervention Type DRUG

Any combination of endocrine therapy and targeted treatment

Combination of chemotherapy, endocrine therapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy, endocrine therapy and targeted treatment(s)

Women with a diagnosis of HR- /HER2- metastatic breast cancer (mBC)

Chemotherapy (exclusive)

Intervention Type DRUG

Administration of any chemotherapeutic agent(s)

Chemotherapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy and targeted treatment(s)

Women with a diagnosis of HR+ /HER2+ metastatic breast cancer (mBC)

Chemotherapy (exclusive)

Intervention Type DRUG

Administration of any chemotherapeutic agent(s)

Endocrine therapy (exclusive)

Intervention Type DRUG

Administration of any type of endocrine therapy

Combination of endocrine therapy and chemotherapy

Intervention Type DRUG

Any combination of endocrine therapy and chemotherapy

Chemotherapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy and targeted treatment(s)

Combination of endocrine therapy and targeted treatment

Intervention Type DRUG

Any combination of endocrine therapy and targeted treatment

Combination of chemotherapy, endocrine therapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy, endocrine therapy and targeted treatment(s)

Women with a diagnosis of HR- /HER2+ metastatic breast cancer (mBC)

Chemotherapy (exclusive)

Intervention Type DRUG

Administration of any chemotherapeutic agent(s)

Chemotherapy and targeted treatment

Intervention Type DRUG

Any combination of chemotherapy and targeted treatment(s)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy (exclusive)

Administration of any chemotherapeutic agent(s)

Intervention Type DRUG

Endocrine therapy (exclusive)

Administration of any type of endocrine therapy

Intervention Type DRUG

Combination of endocrine therapy and chemotherapy

Any combination of endocrine therapy and chemotherapy

Intervention Type DRUG

Chemotherapy and targeted treatment

Any combination of chemotherapy and targeted treatment(s)

Intervention Type DRUG

Combination of endocrine therapy and targeted treatment

Any combination of endocrine therapy and targeted treatment

Intervention Type DRUG

Combination of chemotherapy, endocrine therapy and targeted treatment

Any combination of chemotherapy, endocrine therapy and targeted treatment(s)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

ELIGIBILITY

* female patients older than 18 years
* diagnosis of metastatic breast cancer (de novo disease or first metastatic recurrence) between January 1, 2008, and December 31, 2017
* received a fist-line systemic treatment such as chemotherapy, endocrine therapy or targeted therapy, whatever the sequence (monotherapy or combination of therapies using distinct mechanisms of actions, i.e., polytherapy).

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No